Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Cyclopharm Limited ( (AU:CYC) ) is now available.
Cyclopharm Limited has released its 2024 Annual Report, highlighting its position as a global leader in functional lung ventilation imaging. The report underscores the company’s commitment to innovation and its strong market presence with Technegas™, which is widely used in 66 countries, reflecting its significant impact on the healthcare industry.
More about Cyclopharm Limited
Cyclopharm Limited is a health technology company specializing in functional lung ventilation imaging. Its proprietary product, Technegas™, is a leader in diagnostic imaging and is available in 66 countries.
YTD Price Performance: -24.05%
Average Trading Volume: 164,691
Technical Sentiment Signal: Buy
Current Market Cap: A$133.4M
For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.